This document is a brief summary of current medical practice related to the use of ibogaine for the clinical treatment of behavioral conditions, along with a summary of some of the academic ﬁndings related to ibogaine’s efficacy and effects.
If you’re considering ibogaine treatment, or you’re evaluating it on behalf of someone you know, this information may help you understand how ibogaine has been used medically; what ibogaine treatment is likely to achieve for speciﬁc conditions; and what its effects, side effects, and risks are. It may also help you consider whether ibogaine treatment is a better ﬁt for you than other available treatments for substance abuse or another behavioral condition.
For clinicians and others interested in further research, it will also provide an orientation to the academic literature. This group includes professionals in the ﬁelds of addiction medicine and counseling, psychiatric care, and psychotherapy. Our goal is to help you understand the current state of knowledge about the medically-supervised administration of ibogaine for addiction and other speciﬁc behavioral diagnosis, including what is known about efficacy and risk mitigation.
This document was prepared by Tom Kingsley Brown, Ph.D.
Dr. Thomas Kingsley Brown is a prominent researcher into the effects of altered states of consciousness on behavioral health conditions, and has been investigating ibogaine detox and ibogaine drug treatment since 2009. He has studied the impact of ibogaine on quality of life when used for the treatment of behavioral conditions, and conducted an observational study of the long-term outcomes of ibogaine-assisted treatment for substance dependence. He has a B.S. in chemistry from the University of Pittsburgh, an M.S. from the California Institute of Technology, and a Ph.D. in anthropology from UC San Diego, where he administers a research program for students interested in pursuing doctoral degrees.
Beond Mexico (beond.us) is a residential treatment program in Mexico for people who experience challenges with substance abuse, post-traumatic stress disorder, and other similar behavioral conditions. Conditions like these are the result of both physiological (chemical) and psychological (behavioral) factors, and Beond’s treatments address both, to help people uncover the source of suffering, and put the patient on a path to long-term physical health and spiritual wellness.
Often, a Beond Mexico treatment plan will include the administration of ibogaine, a plant-derived psychoactive pharmaceutical substance that has long been used by indigenous peoples to induce a psychedelic experience. It has been medically established that such a brief and controlled psychedelic experience can disrupt the mental and physical patterns that underpin addiction and other harmful behaviors, leading to permanent life changes and an improved quality of life.
Ibogaine is a medication derived from a West African shrub. Ingesting a large enough dose induces a temporary psychedelic experience that can last several hours, normally with no signiﬁcant side effects. For hundreds of years, indigenous African peoples, such as those practicing the Bwiti tradition, have ingested large doses of Ibogaine in its raw root bark form for its spiritual and healing properties.
Over the past thirty years, Ibogaine has been administered in various clinics around the world for medical treatment purposes, most often to treat drug dependence, including the use of ibogaine for alcoholism and ibogaine for opiate addiction. This is because (as described more fully in this paper):
Because it causes temporary psychedelic effects that can last for several hours, ibogaine is a scheduled drug in many countries, including in the United States, where it is not approved either for medical or for personal use. But it has been used safely and effectively for thirty years, and there is a growing body of evidence -- including academic studies and reports, some of which will be cited here -- that ibogaine is both effective and safe when it is prescribed by a clinician and administered in a medical setting. In some countries, such as New Zealand, ibogaine is now legal for physicians to prescribe and use.
For drug treatment in particular, ibogaine has been used so widely that a consortium of experienced physicians, clinicians, and researchers known as the Global Ibogaine Therapy Alliance have developed a comprehensive set of clinical guidelines for its safe and effective use.
In some of its treatment programs, Beond Mexico prescribes and administers ibogaine to patients, in clinical settings under medical supervision, consistent with the Ibogaine Alliance guidelines. Beond Mexico only uses ibogaine therapy in countries where it is legal.
Indications and Effects
Ibogaine is used to treat addiction to opioids and opiates, alcohol, stimulants, and prescription medications, as well as severe mood disorders, chronic destructive behaviors, and post-traumatic stress disorder (PTSD).
In all three cases, the formal ﬁndings of studies are broadly validated by the professional opinions of clinicians and the medical histories of patients.
For other substance use disorders, the efficacy of ibogaine has not been formally established, but both clinicians and patients report success in treating other substance dependencies with ibogaine. Similarly, as noted below, there are other behavioral disorders beyond substance abuse that have not been formally studied but that clinicians and patients report success in treating with ibogaine.
In both these categories, clinicians describe a pattern of effects, side effects, and risks similar to that documented in studies of opioid use disorder treatment. In other words, based on the early evidence it is very likely that ibogaine can be used to treat a wide variety of behavioral conditions beyond opioid use disorder, with a comparable degree of success.
Virtually all behavioral treatment protocols for substance abuse aim to disrupt routine patterns of behavior to make way for change. In a conventional drug rehabilitation setting, this disruption is achieved over time by low-impact and non-invasive means, such as isolation in a calm (and substance-free) environment and participation in talk therapy, which aim to induce a sense of reﬂection and to generate insights that can be the foundation for change.
The administration of ibogaine also leads to disruptive effects, but unlike other treatments, its effects are abrupt and substantial. The ibogaine ﬂood dose typically triggers a disruption in habitual behaviors and thought patterns, leads soon after to a coalescence of insight into the motivations and effects of those habitual behaviors, and concurrently brings about a short-term suppression of cravings.
Taken collectively, these effects, and the psychological “reset” that they trigger, are believed to be the fundamental mechanism by which ibogaine supports the treatment of behavioral conditions.
In substance abuse treatment, ibogaine acts to reduce cravings, ameliorate withdrawal symptoms both immediately and over time, and contribute to long-term cessation or reduced use; each of these effects has been formally documented through studies. These effects have been shown to continue over time, with patient studies showing persistent positive effects even after 12 months —which is signiﬁcant, given that full cessation or long-term reduction of use is difficult for many persons with substance use disorders to achieve. Patients treated with ibogaine for substance abuse also report a reduction in depressive symptoms over the ensuing months.
It has also been established through studies that administration of ibogaine does not induce cravings for ibogaine itself (i.e., in common parlance, that ibogaine itself is not addictive).
It is noted that ibogaine’s effect in reducing withdrawal symptoms is profound (and in the case of opioids, has been documented in the literature). This differentiates it from psychedelics such as psilocybin and LSD, which have also been successfully used to treat addiction but which do not provide the same palliative beneﬁts. By reducing discomfort and distraction, the mitigation of withdrawal symptoms that ibogaine provides can help the patient better take advantage of the opportunity offered by the psychological disruption it also causes.
As with all substance abuse treatment protocols, the long-term effectiveness of ibogaine therapy is likely to be improved through secondary interventions such as ongoing talk therapy, increased social and family support, habits of self-care and spiritual practice, and pragmatic (e.g., economic) support where applicable.
Ibogaine is widely administered for the treatment of opioid use disorder. In formal clinical studies, treating opioid use disorder with ibogaine has been shown to reduce cravings, signiﬁcantly mitigate withdrawal symptoms, and support cessation or long-term reduced use.
Separate from its value as a treatment for addiction, ibogaine has been shown to potentiate opioid analgesia (to intensify the pain-relieving effects of opioids). This effect has been known since the 1950s; it is now being pharmaceutically commercialized, as a way of enabling patients who take opioids under medical supervision to achieve pain relief at a lower dosage.
The nature of ibogaine’s psychological disruption suggests that it can be similarly eficacious against addiction to other substances, and it is in fact clinically administered to treat addiction to other substances, e.g., cocaine (for which there is clinical evidence of eficacy) and nicotine (for which there is preclinical evidence).
Because the temporary disruption of habitual thoughts and behaviors is believed to be a signiﬁcant driver of ibogaine’s clinical effects, ibogaine is likely to be effective not only against other addictive conditions (e.g., gambling addiction) but also against other conditions and states that are driven by habitual or compulsive behavior (e.g., eating disorders), in which patients might beneﬁt from a like disruptive experience.
Certainly the clinicians who most frequently administer ibogaine in a medical setting, and many of their patients, would concur. And ibogaine has in fact been used successfully, by clinicians experienced in its administration, to treat conditions such as traumatic brain injury, major depressive disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, and bipolar disorder. There is evidence of eficacy for some of these uses (speciﬁcally, for treatment of PTSD, and for alleviation of depressive symptoms in people under treatment for opioid dependency), and research is underway or soon will be in regard to others.
Evidence of ibogaine’s likely wider eficacy also comes through better understanding of its mechanism of action. As one example, as ibogaine affects serotonin uptake, it has been plausibly hypothesized that ibogaine administration could be eficacious against other conditions that are mediated by serotonin, and as noted immediately above it has been successfully used to treat some such conditions.
Ibogaine is a medication derived from the root bark of the West African shrub known as iboga (Tabernanthe iboga). It is typically taken orally, either by ingestion (swallowing) or as a sublingual tincture (liquid placed under the tongue).
In informal settings, especially when taken for its psychotropic effects only, ibogaine is often taken in the form of root bark powder or as a liquid extract (colloquially known as total alkaloid, or TA, extract). These preparations, however, are not always manufactured to the precision or purity standards suitable for medical administration.
Established protocols strongly advise that ibogaine be medically administered in the form of ibogaine hydrochloride, a puriﬁed form of the shrub’s raw root bark extract with some alkaloids removed, rendered as a pill or a powder in a consistent concentration to enable dosed medical administration. This is the form of ibogaine administered at Beond Mexico.
For treatment of drug dependency and other behavioral disorders, ibogaine is typically administered as a single concentrated “ﬂood dose,” causing the body to metabolize a large quantity of ibogaine at once. Administering it in this way contributes to its psycho disruptive effects, which are in turn thought to be a signiﬁcant component of its eficacy against behavioral disorders. In some cases, supplemental doses over a period of days following the ﬂood dose may be indicated.
The clinical effects of ibogaine administration are discussed above; the patient’s experience, including the psychotropic effects, are discussed below.
Reported Experiential Effects of Ibogaine
The state of altered consciousness that is typically induced by the ibogaine primary dose:
— an oneiric, visual, spiritual, and mystical experience — begins within one to two hours of ingestion and lasts for several hours. Many clients relate that this psychotropic experience has lasting psychological and spiritual impact, helping them gain insight into their past and the root causes of their behavior and mindset, and put that insight to use to effect life changes.
There are usually two phases to the experience. The ﬁrst phase is a visionary phase, involving dreamlike psychedelic effects, and typically lasts for 4 to 6 hours. The physiological side effects of ingestion (described below), which most often are not serious in any case, subside once this phase is over. As described more fully below, it is advisable for the patient to be kept comfortable and medically monitored by trained professionals in a clinical environment until the visionary phase concludes.
The visionary phase is followed by an introspective phase, which is primarily responsible for the psychotherapeutic effects. At this point, although their senses may be heightened and they may be distracted, the patient is no longer in the grip of an active psychedelic or “waking dream” experience.
This intensive introspection period, which can last a full day or more, can make it possible for the patient to examine their own fears and behavioral motivations with more clarity and candor than they typically do, and to process memories and lived experience — including traumatic experience — more honestly than usual, as a means to understanding the path to change and resolving to set out on that path.
Following the introspective phase, the direct experience triggered by the ibogaine ﬂood dose is “over.” But the resulting psychological impact, and the impact of the concurrent physiological disruption of habitual behaviors brought on abruptly by the ﬂood dose, often persist long after treatment, helping patients modify their behavior and take steps toward long-term physical healing and spiritual health.
It has long been established — for so long that it is effectively a truism — that healing of all kinds is often enhanced by spirituality and spiritual practice. And in particular, the healing of psychological trauma can be more rapid and more complete when it is supported by a spiritual component.
In regard to addiction in particular, most conventional therapeutic protocols — including both the twelve-step approach to healing, and the talk therapy that is common in conventional drug rehabilitation environments — rest in part on spiritual foundations. And the powerful spiritual experiences people often have during treatment with ibogaine, which often approach or achieve the level of a mystical experience, can facilitate profound transformations in the personal sense of purpose, self-forgiveness, and potential for change. As the famous psychoanalyst Carl Jung suggested many decades ago, an intense religious or mystical experience has the power to enable a person to change the course of their life away from the path of addiction.
The experiences and disruptions induced by the administration of ibogaine can help clear away distractions (including the physiological distraction of withdrawal symptoms), and open the mind to a spiritually informed approach to life and its challenges. Entirely aside from the introspective impact of ibogaine, the spiritual awareness that can arise as a result of the patient’s encounter with ibogaine, even if it is only present in the background and the patient never or rarely engages with it directly, can be its own positive contributor to long-term change.
Since Ibogaine is widely used for the treatment of behavioral conditions such as substance abuse, formal clinical guidelines for the safe administration of ibogaine were developed by a group of physicians and nurses in 2015, based on their own experience and the consensus experience of their peers.
When administered according to these guidelines by medical professionals in a clinical setting, ibogaine is believed to be safe. It has been administered safely around the world over the past 30 years to tens of thousands of patients, many of whom were in the throes of acute substance abuse and dependence.
For cultural reasons, in many countries, psychoactive substances are scheduled drugs, making their possession and use illegal despite their therapeutic value. In the case of ibogaine, its long record of safe administration and the increasing scientiﬁc evidence of its clinical beneﬁt are leading to its descheduling, most signiﬁcantly to its classiﬁcation as an experimental prescription drug in New Zealand in 2010.
Like any pharmacological substance, when administered improperly or in unsafe conditions, Ibogaine can have undesired and potentially serious side effects, including death. But a 2012 research study identiﬁed a total of 19 individuals outside of West Central Africa over 28 years who died within 72 hours of administering Ibogaine. At the time of the study, this was a complete set of all individuals who were known to have died during this period under these conditions.
The study found no evidence that ibogaine itself was inherently toxic; rather, the data suggested that most of the deaths were directly tied to the patients’ advanced pre-existing medical conditions, to using impure product or administering it unsafely, or to the ingestion of opioids during ibogaine treatment.
Contraindications and Interactions
The two most common pre-existing medical conditions that exacerbate the risks of ibogaine treatment are certain cardiovascular conditions (discussed more fully below), and coincident withdrawal from alcohol or benzodiazepines.
The risk of cardiovascular complications can be reduced by ensuring that cardiovascular history is disclosed before treatment, and that the active treatment day involves cardiovascular monitoring and clinical observation. Patients with codependency conditions can taper their alcohol or benzodiazepine use under medical supervision before treatment begins.
Additionally, substances or foods that are broken down by the CYP 450 2D6 enzymes (including grapefruit and quinine) should be avoided before treatment, as they can amplify the physiological effects of ibogaine and make the cardiac risks of treatment more signiﬁcant.
The cardiac abnormalities that ibogaine has been known to induce in rare cases include QTc prolongation (an arrhythmia), bradycardia (slowed heartbeat), and hypotension (lowered blood pressure). Aside from ensuring the comfort of the patient in a potentially disorienting situation, the possibility of these complications is the most important reason why ibogaine should only be administered in a clinical setting with live medical monitoring.
With appropriate screening and live cardiac monitoring, coupled with emergency medical support, these cardiac complications can be identiﬁed if they occur and addressed in real time. These cardiac complications are reversible and the risk does not persist beyond the duration of the ibogaine treatment itself; and there are medical guidelines and protocols for appropriate intervention, should they arise.
In addition to the rare serious side effects, other more common side effects during ibogaine treatment are nausea and vomiting, ataxia (physical imbalance), and anxiety and disorientation, especially during the ﬁrst phase of the psychedelic experience brought on by the ingestion of ibogaine. These effects are not unique to ibogaine; they are also often experienced by people consuming other psychedelic substances.
These side effects are not life-threatening, and are temporary (they subside as the ingested ibogaine is metabolized); but they can be uncomfortable, which is one reason why treatment protocols recommend that patients be accompanied and monitored during treatment.
In the hours or days after treatment, concurrent with and following the period of introspection, patients may experience a sense of psychological elevation and a decreased need for sleep. These effects, too, are temporary.
Serotonin system: The serotonin transporter (SERT) is the site of action of the most common class of antidepressants known as SSRIs (selective serotonin reuptake inhibitors), which include Lexapro, Zoloft, and Prozac. Like SSRIs, ibogaine and its metabolite noribogaine are very strong serotonin reuptake inhibitors (i.e., they raise the level of serotonin). They also act to inhibit the NMDA receptor, which is implicated in depression. Ketamine, which has a similar action, is now being used to treat major depressive disorder.
Serotonin 2A: Ibogaine also facilitates introspection in the context of a psychedelic experience through activation of the serotonin 2A receptor (the main site of action for psilocybin and LSD).
Kappa opioid receptor: A new drug target for the treatment of mood disorders is the kappa opioid receptor. Blocking this receptor has antidepressant and anxiolytic effects. Ibogaine partially blocks this receptor in a manner believed to be central to its therapeutic effects.
GNDF stimulation: Ibogaine stimulates the production of glial-derived neurotrophic factor (GDNF). GDNF can restore damaged dopamine neurons. Many conditions can dysregulate or damage dopamine neurons, including chronic pain, Parkinson's disease, severe drug addiction, and traumatic brain injury (TBI).
We're here to help end your addiction, wherever you are in the process.
Please complete the form below so we can be in contact.
You can expect your first conversation within 24 hours.
Thank you for reaching out to Beond! We have received your inquiry. You can expect to receive a personal response from our professionals as soon as possible (usually 12 hours or less.)
Meanwhile please download our (free) clinical summary on Ibogaine for clinical treatment of behavioral conditions written by renowned researcher Dr. Thomas Kingsley Brown, PhD
Please explore the latest videos about Beond and witness actual client experiences on our Youtube Channel (Beond Ibogaine Treatment for Addiction & Trauma)
Yucatan Peninsula I
Yucatan Peninsula II (2023)
Cabo San Lucas (Opening 2024)
Todos Santos (Opening 2024)
Mexico City (Opening 2024)
Proper preparation ensures the longevity of your healing. Beond counselors and integrations coaches conduct at least two 1:1 confidential sessions to assess your situation and design a pre-treatment plan that prepares your body, mind and spirit for optimal therapy.
Our coaches are available to clients 24 hours a day via our tele-medicine platform.
Led by your physician, supported by our certified nursing and psychology staff, your treatment takes place on-site through a safe and effective combination of psychedelic plant medicine, 1:1 counseling, and advanced medical technologies.
Beond combines experiences of self discovery and exploration with breath work, bodywork, nutrition, meditation and deep relaxation practices.
The key to lasting transformation is continuous aftercare. Your certified Beond integration coaches engage remotely before departure and continue your healing through continuous counseling, education, and support after your return home.
Beond integration coaching is available for extended family & loved ones in any location.